Recent Price Movement and Market Context
On the trading day, Dishman Carbogen Amcis Ltd opened with a gap down of 2.44%, continuing a three-day losing streak that has resulted in a cumulative decline of 10.41%. The stock touched an intraday low of Rs.165.35, representing a 3.98% drop from the previous close. This performance notably lagged behind the Pharmaceuticals & Biotechnology sector, underperforming by 2.27% on the day.
The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum. This technical positioning underscores the challenges the stock faces in regaining investor confidence.
In contrast, the broader market showed signs of resilience. The Sensex, despite opening 1,710.03 points lower, recovered by 266.37 points to trade at 78,795.19, down 1.8% overall. However, the Sensex itself remains below its 50-day moving average, indicating a cautious market environment.
Long-Term Performance and Valuation Metrics
Over the past year, Dishman Carbogen Amcis Ltd has delivered a negative return of 18.55%, significantly underperforming the Sensex, which posted a positive 7.98% return over the same period. The stock’s 52-week high was Rs.321.15, highlighting the extent of the recent decline.
From a valuation perspective, the company exhibits a very attractive Enterprise Value to Capital Employed ratio of 0.6, and a Return on Capital Employed (ROCE) of 3.2%. Despite these valuation metrics suggesting potential value, the company’s fundamental performance remains subdued.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Financial Health and Profitability Concerns
Dishman Carbogen Amcis Ltd’s financial metrics reveal areas of concern. The company’s average ROCE stands at a low 0.97%, indicating limited efficiency in generating returns from capital employed. Net sales have grown at a modest annual rate of 8.10% over the last five years, reflecting subdued top-line expansion.
Profitability has deteriorated sharply in recent quarters. The company reported a quarterly Profit After Tax (PAT) loss of Rs.12.97 crores, representing a decline of 403.0%. Operating profit to interest coverage ratio has fallen to a low of 2.47 times, signalling tighter margins and increased financial strain. Quarterly PBDIT also hit a low of Rs.113.11 crores, underscoring the pressure on earnings before interest, depreciation, and taxes.
Debt and Institutional Participation
Debt servicing capacity remains a challenge, with a high Debt to EBITDA ratio of 4.96 times. This elevated leverage ratio suggests the company faces significant obligations relative to its earnings, which may constrain financial flexibility.
Institutional investors have reduced their holdings by 0.51% in the previous quarter, now collectively holding 8.93% of the company’s shares. This decline in institutional participation may reflect cautious sentiment among investors with greater analytical resources and access to company fundamentals.
Relative Performance and Market Position
Dishman Carbogen Amcis Ltd has underperformed not only the Sensex but also the broader BSE500 index over multiple time frames, including the last three years, one year, and three months. This consistent underperformance highlights challenges in maintaining competitive positioning within the Pharmaceuticals & Biotechnology sector.
Despite the subdued price performance, the company’s profits have risen by 233.1% over the past year, resulting in a low PEG ratio of 0.1. This divergence between profit growth and share price suggests market concerns extend beyond earnings to other fundamental factors.
Holding Dishman Carbogen Amcis Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Ratings and Market Sentiment
MarketsMOJO assigns Dishman Carbogen Amcis Ltd a Mojo Score of 17.0, with a current Mojo Grade of Strong Sell, upgraded from Sell on 12 January 2026. The company’s Market Cap Grade is rated 3, reflecting its mid-tier market capitalisation status. The downgrade in sentiment aligns with the stock’s recent price weakness and fundamental challenges.
On 4 March 2026, the stock recorded a day change of -3.86%, further emphasising the prevailing downward pressure. The stock’s performance relative to sector and benchmark indices, combined with its financial metrics, illustrates the complex factors influencing its valuation and market perception.
Conclusion
Dishman Carbogen Amcis Ltd’s fall to a 52-week low of Rs.165.35 marks a significant milestone in its recent price trajectory. The stock’s underperformance relative to the sector and broader market, coupled with subdued financial indicators such as low ROCE, high leverage, and declining institutional interest, contribute to the current valuation environment. While the company’s profit growth over the past year has been notable, other fundamental factors continue to weigh on investor sentiment and share price performance.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
